Clinical Trial

Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative

Study acronym: ACHELOUS
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 21, 2023 (before its estimated August 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a single arm, multi-center clinical trial. Target population is advanced or metastatic non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients with Programmed Cell Death Ligand 1 (PD-L1) negative, aiming to evaluate the efficacy and safety of the combination therapy of Cadonilimab and chemotherapy. Cadonilimab is a PD-1/CTLA-4 bi-specific antibody.
Trial Details
NCT Number NCT06001151
Lead Sponsor Qian Chu
Collaborators: Akeso Pharmaceuticals, Inc.
Conditions Carcinoma, Non-Small-Cell Lung
Enrollment 49 participants
Start Date 2023-08-07
Primary Completion 2025-08-31 (estimated)
Study Completion 2027-08-31 (estimated)
Updated on ClinicalTrials.gov 2023-08-21